Jurors are nonetheless deliberating over the destiny of Elizabeth Holmes, the founding father of defunct biotech firm Theranos. They’re deciding if she deliberately misled buyers, sufferers, and docs about what her firm’s blood testing expertise might do. Because regardless of large guarantees, the tech the corporate claimed to have invented… didn’t really exist.
And the expertise might by no means be a actuality — no less than not in the way in which Holmes described it. In this episode of our three-part sequence on Theranos, we have a look at what researchers really assume is feasible within the discipline of blood testing and what the longer term might appear to be.